Ultragenyx’s Angelman therapy fails Phase 3, triggering 43% stock drop and cost cuts

Key points

• The Phase 3 'Aspire' trial for apazunersen failed to show efficacy in Angelman syndrome patients, missing the Bayley-4 cognitive score and Multidomain Responder Index endpoints.
• Ultragenyx shares fell 43% after the announcement, reflecting investor disappointment over the loss of a potential blockbuster therapy.
• The company is evaluating the future of the apazunersen program and has announced plans for 'significant expense reductions' to improve financial performance.
• This failure follows a 10% workforce reduction in February and comes shortly after the FDA approved Ultragenyx’s gene therapy Genglycos for glycogen storage disease type Ia.
• Analysts note that the setback may negatively impact the outlook for other companies developing similar antisense therapies for Angelman syndrome, such as Ionis Pharmaceuticals.

Background

Ultragenyx had recently gained momentum with the FDA approval of Genglycos in August 2026 and is awaiting a decision on UX111 for Sanfilippo syndrome. The company previously cut 10% of its workforce in February 2026 following failed brittle bone disease trials. Angelman syndrome currently has no approved disease-modifying treatments, making the failed trial a significant setback for patients and the broader rare disease sector.

How outlets are covering it

Fierce Biotech highlighted the 'refreshingly honest' tone of Ultragenyx’s statement and the immediate 43% stock drop. STAT emphasized the disappointment for families and the broader implications for intellectual disability treatments. BioPharma Dive focused on the financial impact, noting that the loss of apazunersen shifts Ultragenyx from a 'pipeline execution' to a 'commercial and expense' story, with analysts estimating peak sales for the remaining pipeline at $120–$240 million compared to the $1.8 billion potential of the failed drug. William Blair analysts viewed the trial as 'high risk, high reward' and warned of negative read-throughs for other Angelman trials.

Why it matters

The failure of apazunersen represents a major setback for Ultragenyx’s profitability goals and the broader effort to develop treatments for Angelman syndrome. It highlights the risks of relying on single high-potency assets in the rare disease space and may influence investment strategies for companies with similar pipeline profiles. The outcome also underscores the challenges in treating neurogenetic disorders, where previous attempts have often failed.

What to watch

Ultragenyx will decide the disposition of the apazunersen program and implement cost-cutting measures. The company will continue to pursue the approval of UX111 for Sanfilippo syndrome, with a PDUFA date expected in September 2026. Investors will monitor how the company adjusts its operations and whether other companies, such as Ionis, can achieve success with their own Angelman therapies.